Wise's NTC buys ophthalmic portfolio from Novartis

Unquote understands that the acquisition was financed with fresh capital deployed by Wise and a debt package provided by Mediocredito Italiano, which is owned by Intesa Sanpaolo.

Following the acquisition, the company plans to strengthen its product offering in the ophthalmic sector and consolidate its market position in Spain, Italy, Portugal and Poland.

NTC is a Milan-based pharmaceuticals company operating in research, development, registration and commercialisation of drugs, medical devices and food supplements in various sectors, including ophthalmology, pediatrics and gastro-metabolism. The business was founded in 1997 and generates 85% of its revenues from exports to 100 countries. The company intends to open commercial operations in Spain in 2018.

Wise bought NTC in March 2015 via its Wisequity III fund, which held a final close in 2011 on €180m.

The portfolio acquired by NTC from Novartis is composed of ocular antibiotics to treat eye diseases, eye irritation, allergic reactions and inflammation, such as Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside) and Oftalmolosa Cusi Erythromycin (macrolide). Countries covered under the agreement include Spain, Portugal, Italy and Poland.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Southern Europe
• Healthcare
• Italy
• Wise SGR
• Fineurop Soditic
• Intesa Sanpaolo